Serum HER-2/neu as a Prediction and Monitoring Parameter in a Phase II Study with Weekly Paclitaxel in Metastatic Breast Cancer

Elevated levels of the extracellular domain of HER-2/neu in serum (sHER-2/neu) have been shown to be of prognostic importance. In this phase II study with weekly paclitaxel in metastatic breast cancer, we investigated the predictive quality of this serum oncoprotein by correlating the outcome of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2004-03, Vol.24 (2B), p.895-906
Hauptverfasser:	Lüftner, Diana, Henschke, Petra, Flath, Bernd, Akrivakis, Costa, Schnabel, Sonja, Prinz, Berit, Geppert, Rita, Wernecke, Klaus-Dieter, Possinger, Kurt
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - pathology Drug Administration Schedule Enzyme-Linked Immunosorbent Assay Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Monitoring, Physiologic - methods Neoplasm Metastasis Paclitaxel - therapeutic use Receptor, ErbB-2 - blood Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!